Molecular basis for two different affinity states of the interleukin 2 receptor: affinity conversion model. 1986

S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo

Two affinity species of the interleukin 2 (IL-2) receptor are different states of a single receptor molecule. We assumed that a binary complex between the IL-2 receptor and another lymphocyte-specific protein would constitute the high-affinity receptor. To test this assumption, we counted the numbers of IL-2 receptors with high and low affinity in a murine T-cell line CT/hR-1 that expresses not only murine but also human receptors by cDNA transfection. We found that human high-affinity receptors disappeared when the murine high-affinity receptors were already occupied by the ligand. The results were incompatible with a fixed number of human and murine receptors with high affinity in CT/hR-1 cells. We suggest that the high-affinity state of the IL-2 receptor is a ternary complex of IL-2, the IL-2 receptor, and a postulated "converter" protein, which is fewer in number than the receptors. The converter would be unable to form a complex with the IL-2 receptor unless IL-2 was already bound to it. The ligand binding to the receptor would cause a conformational change in the receptor, increasing its affinity to the converter. Ternary complex formation would, in turn, change the apparent affinity of the receptor to the ligand from low to high by reduction of the dissociation constant.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
August 1991, The EMBO journal,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
September 1990, Cytokine,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
November 1988, Molecular immunology,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
September 2021, Proteins,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
January 1987, The Journal of experimental medicine,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
April 1988, Molecular biology & medicine,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
March 2019, Journal of colloid and interface science,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
July 1988, European journal of immunology,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
September 1988, Journal of chromatography,
S Kondo, and A Shimizu, and Y Saito, and M Kinoshita, and T Honjo
March 1979, Biochemical pharmacology,
Copied contents to your clipboard!